Literature DB >> 12102641

Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.

James W McAuley1, Gail D Anderson.   

Abstract

Although epilepsy affects men and women equally, there are many women's health issues in epilepsy, especially for women of childbearing age. These issues, which include menstrual cycle influences on seizure activity (catamenial epilepsy), interactions of contraceptives with antiepileptic drugs (AEDs), pharmacokinetic changes during pregnancy, teratogenicity and the safety of breastfeeding, challenge both the woman with epilepsy and the many healthcare providers involved in her care. Although the information in the literature on women's issues in epilepsy has grown steeply in recent years, there are many examples showing that much work is yet to be done. The purpose of this article is to review these issues and describe practical considerations for women of childbearing age with epilepsy. The article addresses the established or "first-generation" AEDs (phenobarbital, phenytoin, primidone, carbamazepine, ethosuximide and valproic acid) and the "second-generation" AEDs (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide). Although a relationship between hormones and seizure activity is present in many women, good treatment options for catamenial epilepsy remain elusive. Drug interactions between enzyme-inducing AEDs and contraceptives are well documented. Higher dosages of oral contraceptives or a second contraceptive method are suggested if women use an enzyme-inducing AED. Planned pregnancy and counselling before conception is crucial. This counselling should include, but is not limited to, folic acid supplementation, medication adherence, the risk of teratogenicity and the importance of prenatal care. AED dosage adjustments may be necessary during pregnancy and should be based on clinical symptoms, not entirely on serum drug concentrations. Many groups have turned their attention to women's issues in epilepsy and have developed clinical practice guidelines. Although the future holds promise in this area, many questions and the need for progress remain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12102641     DOI: 10.2165/00003088-200241080-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  159 in total

1.  Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child.

Authors:  B Rambeck; G Kurlemann; S R Stodieck; T W May; U Jürgens
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

2.  Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy.

Authors:  A Ornoy; E Cohen
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

Review 3.  Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study.

Authors:  W B Kannel; W P Castelli; T Gordon
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

4.  Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight.

Authors:  C L Hvas; T B Henriksen; J R Ostergaard; M Dam
Journal:  BJOG       Date:  2000-07       Impact factor: 6.531

Review 5.  Bone complications of anticonvulsants.

Authors:  T J Hahn
Journal:  Drugs       Date:  1976       Impact factor: 9.546

6.  Anticonvulsants and congenital malformations.

Authors:  S S Jick; B Z Terris
Journal:  Pharmacotherapy       Date:  1997 May-Jun       Impact factor: 4.705

7.  Intrauterine growth in the offspring of epileptic women: a prospective multicenter study.

Authors:  D Battino; S Kaneko; E Andermann; G Avanzini; M P Canevini; R Canger; D Croci; C Fumarola; L Guidolin; D Mamoli; F Molteni; G Pardi; A Vignoli; Y Fukushima; R Kan; A Takeda; Y Nakane; Y Ogawa; L Dansky; M Oguni; I Lopez-Ciendas; A Sherwin; F Andermann; M H Seni; M Goto
Journal:  Epilepsy Res       Date:  1999-08       Impact factor: 3.045

8.  Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years.

Authors:  G Kafali; T Erselcan; F Tanzer
Journal:  Clin Pediatr (Phila)       Date:  1999-02       Impact factor: 1.168

Review 9.  Reproductive function in epilepsy.

Authors:  J A Cramer; E E Jones
Journal:  Epilepsia       Date:  1991       Impact factor: 5.864

Review 10.  Sexual dysfunction in epilepsy.

Authors:  M J Morrell
Journal:  Epilepsia       Date:  1991       Impact factor: 5.864

View more
  7 in total

Review 1.  Management of epilepsy during pregnancy: an update.

Authors:  Sima I Patel; Page B Pennell
Journal:  Ther Adv Neurol Disord       Date:  2015-12-27       Impact factor: 6.570

Review 2.  Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?

Authors:  Naghme Adab
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Epilepsy Res       Date:  2009-04-29       Impact factor: 3.045

Review 4.  [Drug interactions with antiepileptic agents].

Authors:  Klaus Turnheim
Journal:  Wien Klin Wochenschr       Date:  2004-02-28       Impact factor: 1.704

Review 5.  Neuroendocrine aspects of catamenial epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Horm Behav       Date:  2012-05-02       Impact factor: 3.587

Review 6.  Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review.

Authors:  Gali Pariente; Tom Leibson; Alexandra Carls; Thomasin Adams-Webber; Shinya Ito; Gideon Koren
Journal:  PLoS Med       Date:  2016-11-01       Impact factor: 11.069

7.  Pharmacokinetic characteristics of antiepileptic drugs (AEDs).

Authors:  Marketa Marvanova
Journal:  Ment Health Clin       Date:  2016-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.